Assisted living mental health services fell between 2019 and 2020, study finds
By
Kristen Fischer
Apr 25, 2024
Mental health visits for assisted living residents living with dementia dropped as the pandemic set in, a new study finds.
Navigating insurance for those with dementia a major challenge for family caregivers
By
Kathleen Steele Gaivin
Jan 30, 2024
Family caregivers face many challenges in helping their loved ones who are living with dementia, not the least of which is navigating the insurance landscape for long-term care. That’s according to the...
UCSF telehealth program cuts costs and improves outcomes for seniors with dementias
By
Aaron Dorman
Sep 25, 2023
A telehealth program out of UCSF has achieved the coveted goal of cutting costs and improving patient care for seniors with dementia, researchers state.
CMS announces Alzheimer’s drug coverage policy, but ‘the devil is in the details,’ experts say
By
Kimberly Bonvissuto
Jun 01, 2023
A Thursday announcement by the Centers for Medicare & Medicaid Services regarding coverage of Alzheimer’s drugs is being met with skepticism by some industry advocates who say that “the devil is in...
More news for Monday, Nov. 7
By
Kimberly Bonvissuto
Nov 07, 2022
HUD opens 5th round of COVID supplemental payments, reduces reimbursements for senior housing … Front Porch expands memory care programs to meet increasing demand … Active adult data now available...
More news for Wednesday, Feb. 22
By
Kimberly Bonvissuto
Feb 22, 2023
Congressman tells AG Garland that Esformes case is ‘political’ … FHCA unveils 2023 legislative priorities … Medicare advisers suggest tweak to coverage process for Alzheimer’s drugs … Schumer...
Failing to cover Alzheimer’s therapies a costly proposition: researchers
By
Kimberly Bonvissuto
Jun 16, 2023
Not managing Alzheimer’s disease and related dementias is a costly proposition not just to families, but also to society, according to two recent studies.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
Medicare monthly premiums to drop for seniors
Sep 28, 2022
The fee cuts come at the same time as seniors receive a Social Security cost-of-living increase for 2023 of up to 9 or 10%.